Proteomic Differences between Developmental Stages of *Toxoplasma gondii* Revealed by iTRAQ-Based Quantitative Proteomics

Ze-Xiang Wang1, Chun-Xue Zhou1,2, Hany M. Elsheikha3, Shuai He1,4, Dong-Hui Zhou1,4* and Xing-Quan Zhu1,5

1 State Key Laboratory of Veterinary Etiological Biology, Key Laboratory of Veterinary Parasitology of Gansu Province, Lanzhou Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Lanzhou, China, 2 National Animal Protozoa Laboratory and College of Veterinary Medicine, China Agricultural University, Beijing, China, 3 Faculty of Medicine and Health Sciences, School of Veterinary Medicine and Science, University of Nottingham, Loughborough, United Kingdom, 4 College of Animal Science and Technology, Anhui Agricultural University, Hefei, China, 5 Jiangsu Co-Innovation Center for Prevention and Control of Important Animal Infectious Diseases and Zoonoses, Yangzhou, China

*Correspondence:* Dong-Hui Zhou zhoudonghui@caas.cn

**Open Access**

**Edited by:** Guan Zhu, Texas A&M University, United States

**Reviewed by:** Xiaomeng Shen, Amgen, United States, Stanley Dean Rider, Wright State University, United States

**Specialty section:** This article was submitted to Infectious Diseases, a section of the journal Frontiers in Microbiology

**Received:** 18 March 2017  
**Accepted:** 16 May 2017  
**Published:** 02 June 2017

**Citation:** Wang Z-X, Zhou C-X, Elsheikha HM, He S, Zhou D-H and Zhu X-Q (2017) Proteomic Differences between Developmental Stages of *Toxoplasma gondii* Revealed by iTRAQ-Based Quantitative Proteomics. Front. Microbiol. 8:985. doi: 10.3389/fmicb.2017.00985

*Toxoplasma gondii* has a complex two-host life-cycle between intermediate host and definitive host. Understanding proteomic variations across the life-cycle stages of *T. gondii* may improve the understanding of molecular adaption mechanism of *T. gondii* across life-cycle stages, and should have implications for the development of new treatment and prevention interventions against *T. gondii* infection. Here, we utilized LC–MS/MS coupled with iTRAQ labeling technology to identify differentially expressed proteins (DEPs) specific to tachyzoite (T), bradyzoites-containing cyst (C) and sporulated oocyst (O) stages of the cyst-forming *T. gondii* Pru strain. A total of 6285 proteins were identified in the three developmental stages of *T. gondii*. Our analysis also revealed 875, 656, and 538 DEPs in O vs. T, T vs. C, and C vs. O, respectively. The up- and down-regulated proteins were analyzed by Gene Ontology enrichment, KEGG pathway and STRING analyses. Some virulence-related factors and ribosomal proteins exhibited distinct expression patterns across the life-cycle stages. The virulence factors expressed in sporulated oocysts and the number of up-regulated virulence factors in the cyst stage were about twice as many as in tachyzoites. Of the 79 ribosomal proteins identified in *T. gondii*, the number of up-regulated ribosomal proteins was 33 and 46 in sporulated oocysts and cysts, respectively, compared with tachyzoites. These results support the hypothesis that oocyst and cystic stages are able to adapt to adverse environmental conditions and selection pressures induced by the host’s immune response, respectively. These findings have important implications for understanding of the developmental biology of *T. gondii*, which may facilitate the discovery of novel therapeutic targets to better control toxoplasmosis.

**Keywords:** *Toxoplasma gondii*, life-cycle, mass spectrometry, proteomics, iTRAQ, differentially expressed protein (DEP)
INTRODUCTION

Toxoplasma gondii infection represents a significant global health burden, with considerable social and economic implications. This parasite can infect all vertebrate animals and humans (White et al., 2014). Although most immuno-competent individuals do not develop clinical disease, T. gondii infection in immuno-compromised individuals, such as AIDS or cancer patients, can cause severe encephalitis and retinocchoroiditis (Suzuki et al., 1996; Kijlstra and Jongert, 2008; Herrmann et al., 2012). Also, congenital infection with T. gondii is a major cause of spontaneous abortion, preterm labor, or significant diseases in the survived neonate (Montoya and Liesenfeld, 2004). Current treatments are expensive and toxic (McLeod et al., 2006); and together with the lack of a vaccine makes the need for new therapeutic agents very urgent. Development of new treatment and prevention approaches including anti-T. gondii drugs and vaccines can be most potent if targeted at specific life-cycle stages and/or specific proteins expressed at these developmental stages. Therefore, better understanding of the developmental biology and stage-specific molecular determinants of the life-cycle stages is urgently needed.

Toxoplasma gondii has a complex, two-host life-cycle that involves both asexual (takes place in any vertebrate animal as an intermediate host) and sexual (occurs only in the felid definitive host) reproductive cycles (Blader et al., 2015). The sexual cycle of T. gondii occurs exclusively in the enteropithelial cells of the intestine of the felid host (Behnke et al., 2014) and culminates in the production of oocysts, which are adapted to survive under adverse climatic conditions (Dubey, 2010). Toxoplasma gondii oocysts are shed non-sporulated (non-infective) in cat feces, and in a few days they undergo a sporulation process in the environment and with appropriate climatic conditions they mature to sporulated oocysts. In the intermediate host, T. gondii undertakes asexual reproduction cycle, which follows ingestion of sporulated oocysts or ingestion of tissue containing T. gondii cysts full of bradyzoites (Dattoli et al., 2011). Asexual cycle involves two different tissue stages produced in different phases of the infection process and play different roles. These two stages exist as a replicative tachyzoite stage (Hehl et al., 2015), which can transform to slowly replicating bradyzoites within a tissue cyst, which are commonly found in the central nervous system (Bohne et al., 1999). Both of tachyzoite and bradyzoite are infective to cats.

Advances in proteomic technologies have already contributed to an increasing understanding of the protein expression in T. gondii. For example, in 2002 the first proteome map of T. gondii tachyzoite was constructed using 2-dimensional electrophoresis (2-DE) combined with matrix-assisted laser-desorption/ionization time of flight mass spectrometry (MALDI-TOF-MS) (Cohen et al., 2002). Zhou et al. employed two-dimensional difference gel electrophoresis (2D-DIGE) coupled with MALDI-TOF-MS to compare the differentially expressed proteins of four different genotypes of T. gondii tachyzoites (Zhou et al., 2014). Also, proteins expressed by oocysts and sporozoites of T. gondii have been studied (Fritz et al., 2012; Possenti et al., 2013). However, global protein expression patterns across the developmental stages of T. gondii have yet to be determined. In order to understand the functional differences among different stages of T. gondii life-cycle it is important to identify and quantify the protein’s content of these stages.

Comparative proteomic analysis requires the use of exceptionally sensitive mass spectrometric approaches. In this study, we utilized LC-MS/MS analysis coupled with isobaric tags for relative and absolute quantification (iTRAQ) labeling and SCX fractionation to identify and quantify differentially expressed proteins of different stages of T. gondii life-cycle. iTRAQ is a quantitative proteomic method that can generate information on the abundance of hundreds of proteins at one time. Also, it allows parallel biological or technical replicates to be multiplexed (4-plex or 8-plex iTRAQ labeling) in one LC-MS/MS experiment, thus overcomes the inter-assay variations that occur in a single MS-based shotgun profiling experiment (Wu et al., 2006; Pierce et al., 2008; Craft et al., 2013). Also, this method has been successfully used to determine the differentially expressed proteins of T. gondii oocysts during sporulation (Zhou et al., 2016). The present study aimed to unravel the set of proteins that are unique to three life-cycle stages of T. gondii, namely oocyst, tachyzoite, and bradyzoites-containing cyst using 8-plex iTRAQ labeling and LC-MS/MS. We identified differentially expressed proteins, which are specific to the three infective life-cycle stages of T. gondii.

MATERIALS AND METHODS

Ethics Approval

All protocols were reviewed and approved by the Animal Ethics Committee of Lanzhou Veterinary Research Institute, Chinese Academy of Agricultural Sciences. The experiments were performed in a strict accordance with the Animal Ethics Procedures and Guidelines of the People’s Republic of China. All efforts were made to minimize suffering of the animals.

Mice, Cats, and Parasite Strain

Six to eight week-old female BALB/c mice and 10 week-old female kitten were obtained from Laboratory Animal Center of Lanzhou Veterinary Research Institute. Type II Prugniaud (PRU) strain of T. gondii was maintained in our laboratory by passaging the cysts in mice as described previously (Zhou et al., 2016).

Preparation of Parasite Materials

Collection of Tachyzoites

Tachyzoites of Type II Prugniaud (PRU) strain were collected using a previously described method (Zhou et al., 2011, 2014).
Briefly, specific-pathogen free (SPF) mice were treated with 0.2 mg of dexamethasone (DSMS) every other day for three times and then inoculated orally with 100–150 cysts. Nine days after infection the peritoneal cavity was rinsed with sterile phosphate-buffered saline (PBS, 137 mM NaCl, 2.7 mM KCl, 10 mM Na₂HPO₄, 2 mM KH₂PO₄) to harvest the tachyzoites. Then, the peritoneal wash containing the tachyzoites was collected and centrifuged for 15 min at 1,680 g followed by two further washes with PBS. After the final wash the supernatant was decanted and the pellet was digested with 0.25% trypsin at 37 °C for 20 min and centrifuged for 15 min at 1,680 g. The supernatant was removed and the final protein pellet was suspended in 1 mL PBS and was kept in an Eppendorf tube at −80 °C until analysis.

**Isolation and Purification of Cysts**

Mice were infected orally with 100–150 *T. gondii* cysts and were humanely sacrificed 4 weeks later. Mouse brains were collected and grinded with a pestle and mortar. During grinding, 1 mL of PBS per mouse brain was added slowly as grinding proceeds. The brain homogenate was layered on the top of Lymphocyte Separation Medium (Solarbio, Beijing, China) in a plastic tube followed by centrifugation at 2,290 g for 30 min. The parasite cysts were harvested and kept at −80 °C until use.

**Preparation of Sporulated Oocysts**

Specific-pathogen-free kitten was infected with 200 cysts recovered from mouse brain and its feces was collected daily to isolate oocysts using caesium chloride (CsCl) centrifugation method as described previously (Staggs et al., 2009). Briefly, fecal samples were mixed in water and filtered through 250 µm mesh. The filtrates were pelleted by centrifugation and the supernatant was discarded. Following three washes in PBS, the supernatant was discarded and the pellet was mixed with 5 volumes of sucrose solution with 1.15 specific gravity. The supernatant containing oocysts were collected, suspended in TE buffer (10 mM Tris-HCl, 1 mM EDTA, pH 8.0) and centrifuged using discontinuous CsCl gradient method. Oocysts at the opaque-to-white layer interface were collected and washed with 0.85% saline. Finally, the oocyst pellet was suspended in PBS and maintained at 4 °C for 20 min. The parasite cysts and tachyzoites were labeled with 100 µl 0.25M TEAB (triethyl ammonium bicarbonate) three times at 13,400 g for 20 min. Solution at the bottom of ultracentrifugation was discarded and the ultracentrifugation was centrifuged with 100 µl 0.25M TEAB with 70% ethanol and deionized water, the protein solution was poured into ultrafiltration cartridge and centrifuged at 13,400 g for 20 min. Solution at the bottom of ultrafiltration was discarded and the ultracentrifugation was centrifuged with 100 µl 0.25M TEAB (triethyl ammonium bicarbonate) three times at 13,400 g for 20 min. The protein pellets were reconstituted in 50 µl of 6 M urea/50 mM TEAB with sonication (Possenti et al., 2013) and digested in 2% trypsin overnight (Promega). Then, the digested peptides were dried and reconstituted in 0.5 M TEAB. Then, peptides were labeled according to the instructions of 8-plex iTRAQ kit (Applied Biosystems/MDS Sciex, Foster City, CA). Label reagent mixed with 150 µl isopropyl alcohol was mixed with samples and incubated for 2 hr at ambient temperature. The reaction was terminated with deionized water and samples were thoroughly mixed. Following vacuum centrifugation, dried samples were preserved at −80 °C until use. Proteins of sporulated oocysts were labeled with 115 and 116, whereas the proteins of the cysts and tachyzoites were labeled with 117, 118, and 119, 121, respectively.

**SCX Fraction and LC-MS/MS Analysis**

Strong cation exchange (SCX) fractionation chromatography was performed using the high performance liquid chromatography (HPLC) system (Phenomenex columns; Gemini-NX 3u C18 110A; 150*2.00 mm). The iTRAQ-labeled peptides were separated by a linear gradient formed by mobile phase A (20 mM HCOONH₄, pH 10) and mobile phase B (20 mM HCOONH₄, 80% ACN, pH 10). The flow of peptides elution was set to a constant rate of 200 µl/min. A total of 24 fractions were collected by a linear gradient (1 collection every 1 min, 100 min) and were acidified with trifluoroacetic acid (50%). The fractions were vacuum-dried for further analysis with LC-MS. Fractions (96 µg) were dissolved in buffer A [0.1% formic acid, 2% acetonitrile (ACN)] and pelleted at 13,447 g for 20 min. The supernatant was loaded onto analytical columns and was identified with an online Q Exactive system (Thermal Scientific). Component of mobile phase A and mobile phase B of LC-MS was formic acid (0.1%) and 80% ACN containing 0.1% formic acid, respectively. The flow rate of analytical columns was set at 350 nl/min and the peptides were analyzed within 65 min 3-step gradient (80% ACN in 0.1% formic acid from 4 to 50% over 45 min, 50 to 90% over 5 min and kept at 90% for 5 min). The parameters of the first grade MS included scan ranges from 350 to 1,800 m/z at

The concentration of the protein was determined by the protein quantitative kit (QuantiProTM BCA Assay Kit, Sigma).

**Protein Digestion and iTRAQ Labeling**

For protein digestion, 100 µg protein of each sample was reduced, alkylated, and then precipitated with the methanol/chloroform precipitation method. Firstly, 50 mM Reducing Reagent (final concentration, 8-plex iTRAQ kit, AB Sciex, USA) were added into each sample followed by incubation at 60 °C for 1 hr. Then, the sample was mixed with 200 mM Cysteine-Blocking Reagent (final concentration, 8-plex iTRAQ kit, AB Sciex, USA) and held at ambient temperature for 10 min. Following rinsing the 10 KD ultrafiltration cartridge with 70% ethanol and deionized water, the protein solution was centrifuged with 13,400 g for 20 min. Solution at the bottom of ultrafiltration was discarded and the ultracentrifugation was centrifuged with 100 µl 0.25M TEAB (triethyl ammonium bicarbonate) three times at 13,400 g for 20 min. The protein pellets were reconstituted in 50 µl of 6 M urea/50 mM TEAB with sonication (Possenti et al., 2013) and digested in 2% trypsin overnight (Promega). Then, the digested peptides were dried and reconstituted in 0.5 M TEAB. Then, peptides were labeled according to the instructions of 8-plex iTRAQ kit (Applied Biosystems/MDS Sciex, Foster City, CA). Label reagent mixed with 150 µl isopropyl alcohol was mixed with samples and incubated for 2 hr at ambient temperature. The reaction was terminated with deionized water and samples were thoroughly mixed. Following vacuum centrifugation, dried samples were preserved at −80 °C until use. Proteins of sporulated oocysts were labeled with 115 and 116, whereas the proteins of the cysts and tachyzoites were labeled with 117, 118, and 119, 121, respectively.
a resolution of 70,000 with a maximum injection time of 40 ms. The second grade MS spectra were acquired in a resolution of 17,500 with 60 ms maximum injection time and the 20 top precursors for each MS cycle were selected.

Database Search and Bioinformatics Analysis

The raw MS data was transformed into mascot generic format (.mgf) files with Proteome Discoverer™ 1.4 and the data file was used to query T. gondii ME49 strain database (http://www.toxodb.org/common/downloads/release-10.0/TgondiiME49/fasta/data/), which contains 8322 protein sequences. The ProteinPilot™ Software 4.5 (AB SCIEX) was used to further identify and quantify proteins. To filter the results, we employed false discovery rate (FDR) of less than 0.01 for identification and the confidence level of 95% or unused confidence score larger than 1.3 for quantification. For differentially expressed proteins (DEPs), those with \(|\log_2 \text{fold change}|>1\) were deemed upregulated or downregulated proteins, respectively.

Functional classification of the DEPs was performed according to Gene Ontology (GO) annotation and enrichment (http://www.geneontology.org) analysis. The DEPs were classified into three categories, namely molecular function, biological process and cellular component. The Kyoto Encyclopedia of Genes and Genomes (KEGG) (http://www.kegg.jp/kegg/) was used to predict molecular function, biological processes and significant DEPs pathways. Protein-protein interactions (PPI) were predicted in the Search Tool of the Retrieval of Interaction Genes/Proteins (STRING) database and the interaction network was illustrated by Cytoscape software. The PPI whose combined score was >0.9 were subjected to further interaction network analysis.

RESULTS

Overview of Primary Data and Protein Identification

iTRAQ was used to identify the proteomic differences among life-cycle stages of T. gondii, namely sporulated oocyst, tachyzoite, bradyzoites-containing cyst. Representative SCX chromatogram of the results is shown in Figure S1. A total of 6,285 proteins were identified from 53,335 peptides, which were matched with 76,534 spectra at a false discovery rate of 1%. Multiple proteins were identified, among which, 1667, 1697, and 1791, proteins were identified in O vs. T (oocysts vs. tachyzoites), T vs. C (tachyzoites vs. cysts) and C vs. O (cysts vs. oocysts), respectively after filtration (CV \(\leq 0.5\)) (Tables S1–S3). Using 99% confidence level (CV \(\leq 0.5\)), 1602, 1625, and 1719 proteins were identified in O vs. T, T vs. C, and O vs. C, respectively (Tables S4–S6). Compared with analysis using 95% confidence level, 65 proteins, 72 proteins and 72 proteins were lost in O vs. T, T vs. C, and C vs. O, respectively. Repeatability analysis based on the Coefficient of variation (CV) showed that 79.3, 81.8, and 90.7% proteins can be covered in the total identified proteins in O vs. T, T vs. C, and C vs. O, respectively, when the CV was less than 0.5 (Figure 1).

Protein Quantification and Hierarchical Clustering Analysis

In brief, 875 proteins, 656 proteins, and 538 proteins were defined as differentially expressed protein (DEPs) in O vs. T, T vs. C and C vs. O, respectively (\(|\log_2 \text{fold change}|>1\) and \(P < 0.05\)) (Tables S7–S9). Among DEPs in each group, 801 proteins and 74 proteins were upregulated or downregulated in oocyst compared with tachyzoite stage. There were 146 upregulated proteins and 510 downregulated proteins in T vs. C. Further, 180 proteins and 358 proteins had higher or lower expression level in cyst than in oocyst. Numbers of DEPs in different level are presented in Figure 2. Results of the hierarchical clustering analysis of the identified proteins are shown in Figure 3.

Gene Ontology Analysis of DEPs

The DEPs were subjected to functional classification by Gene Ontology (GO) analysis. We identified 3371, 2846, and 1998 GO terms in O vs. T, T vs. C and C vs. O, respectively. Among these GO terms, there were 1708 molecular function terms, 874 biological process terms and 789 cellular component terms in O vs. T. GO terms in T vs. C included 1392 molecular function terms, 832 biological process terms, 622 cellular component terms and GO terms in C vs. O included 1083 molecular function terms, 634 biological process terms and 281 cellular component terms. Those GO terms were classified and enriched in order to investigate the properties of upregulated and downregulated proteins in each group. The most 40 enriched GO terms in each group and their destination to three main GO categories are presented in Figure 4.

As is shown in Figure 4A, for O vs. T, the top five enriched GO terms for upregulated proteins within molecular function were ion binding, oxidoreductase activity, kinase activity, peptidase activity and structural constituent of ribosome. The top five enriched GO terms for downregulated proteins were kinase activity, DNA binding, helicase activity, RNA binding, and oxidoreductase activity. Translation, small molecule metabolic process, catabolic process, cellular nitrogen compound metabolic process and transport were the five top terms for upregulated proteins under biological process. The top five enriched GO terms for downregulated proteins in biological process were cellular nitrogen compound metabolic process, biosynthetic process, small molecule metabolic process, cellular protein modification process, and DNA metabolic process. The most abundant GO terms for upregulated proteins under cellular component were intracellular, followed by protein complex, cytoplasm, ribosome and nucleus. Protein complex, nucleus, chromosome, cytoplasm and intracellular were the five top terms for downregulated proteins.

With regard to GO enrichment for upregulated proteins in T vs. C, ion binding, biosynthetic process, extracellular region were the most enriched terms in molecular function, biological process and cellular component respectively. For downregulated proteins, ion binding, structural constituent of ribosome, RNA binding were the top three terms under molecular function and translation, cellular nitrogen compound metabolic process,
transport were the most three enriched terms under biological process. The top five terms within cellular component included intracellular, cytoplasm, protein complex, ribosome, nucleus (Figure 4B).

Among molecular function terms in C vs. O, ion binding, oxidoreductase activity, ligase activity, kinase activity and DNA binding were the mostly prevalent terms for upregulated proteins. The most five prominent terms for downregulated proteins were ion binding, oxidoreductase activity, kinase activity, peptidase activity, and lyase activity. Biosynthetic process and small molecule metabolic process occupied top one position in biological process for upregulated proteins and downregulated proteins respectively. The mostly enrichment terms within cellular component for upregulated proteins
KEGG Pathway Analysis of DEPs

To identify the biological pathways operating during *T. gondii* development, we mapped the DEPs in each group to reference pathways contained in the KEGG pathway database. Among DEPs identified in each group, 401 DEPs, 654 DEPs, 536 DEPs had a KEGG Orthology (KO) ID and could be mapped to 55 pathways, 55 pathways, 61 pathways in O vs. T, T vs. C, and C vs. O, respectively. Of the 55 enriched pathways in group O vs. T, 42 pathways were upregulated and no pathway was downregulated. The top 5 enriched upregulated pathways were metabolic pathways, biosynthesis of secondary metabolites, biosynthesis of antibiotics, carbon metabolism, and ribosome (Figure 5A).

There were 5 upregulated pathways and 13 downregulated pathways in T vs. C. Ribosome, fatty acid metabolism, biosynthesis of unsaturated fatty acids, alpha-Linolenic acid metabolism, galactose metabolism were upregulated pathways and the top 5 enriched downregulated pathways included metabolic pathways, carbon metabolism, aminoacyl-tRNA biosynthesis, RNA transport, and protein processing in endoplasmic reticulum (Figure 5B).

In C vs. O, 2 and 25 pathways were up- and downregulated, respectively. The up-regulated pathways included aminoacyl-tRNA biosynthesis, pyruvate metabolism and the five most enriched downregulated pathways were metabolic pathways, biosynthesis of secondary metabolites, biosynthesis of antibiotics, carbon metabolism, and biosynthesis of amino acids (Figure 5C).

Analysis of Virulence Factor Expression

To study the expression pattern of virulence factors across the life-cycle stages of *T. gondii*, the expression levels of 23 virulence factors, which simultaneously appear in all groups were analyzed. None of these virulence factors were downregulated and 20 factors were upregulated in oocyst compared with tachyzoite except RON4, PHIL1, and RON5 (Figure 6A). In T vs. C, while five virulence factors (SPATR, PP2C, VP1, ROP5, AMA1) were upregulated in tachyzoite vs. cyst, the number of downregulated virulence factors was 10 (RON5, ROP16, RON2, GRA4, MIC3, ROP2A, GRA1, GRA6, GRA7, MIC6) (Figure 6B). The outcome of comparison between C and O was similar to O vs. T. No virulence factor exhibited higher expression level in cyst and 11 virulence factors were upregulated in the oocysts (GRA7, ROM4, MIC3, MIC6, PP2C, ROP18, VP1, AMA1, MIC2, SPATR, ROP5) (Figure 6C).

Expression Pattern of Ribosomal Proteins

The differences of ribosomal protein expression among the different life-cycle stages showed upregulation of 33 and 46 ribosomal proteins in oocyst and in cyst, compared to tachyzoite. Six ribosomal proteins had higher expression level in cysts compared with oocyst (Table 1).

DISCUSSION

In order to understand the functional differences across the different life-cycle stages of *T. gondii*, it is important to identify,
quantify and compare the protein repertoire of each of these life cycle forms. In the context of host-pathogen interaction, such insights have the potential to reveal new mechanistic determinants of *T. gondii* infectivity and adaptation. In this study, we applied iTRAQ labeling coupled with LC-MS/MS approach to profile and compare the proteome of *T. gondii* oocysts, tachyzoites and bradyzoites-containing cysts. A total of 6285 proteins were identified in the three developmental stages of *T. gondii*. The comparative analysis identified significant differences in the level of expressed proteins when comparing oocysts to tachyzoites (875 proteins), tachyzoites to cysts (656 proteins) and cysts to oocysts (538 proteins). Based on GO and KEGG analyses, ribosomal proteins and proteins involved in macromolecule metabolism were the predominant groups.

A number of virulence-related factors and ribosomal proteins exhibited distinct expression patterns across the life-cycle stages. Some virulence factors can be upregulated during the sporulation of oocysts (Wu et al., 2006). In our study, a number of proteins with a virulence function have been identified. Compared with oocysts, none of virulence factors was significantly overexpressed in tachyzoite and cyst stages. By contrast, 23 and 11 virulence factors were upregulated in oocyst compared with tachyzoites and cysts, respectively. This indicates that oocysts expressed more virulence factors compared to other stages of the life-cycle of *T. gondii*. Interestingly, the number of upregulated virulence factors was twice the number of downregulated factors in cyst compared with tachyzoite. These findings seem consistent with previous data, which reported that genes coding for β-oxidation enzymes are not expressed in tachyzoites, but may be active in oocysts (Possenti et al., 2013). Additionally, the dense granule protein GRA1 (a specific protein that is known to be expressed at the transformation from tachyzoites to bradyzoites) was found down-regulated in tachyzoites compared to cysts in our study. This finding is also consistent with pervious work, which reported a progressive suppression in the expression of this protein during the formation of bradyzoites-containing tissue cysts (Cleary et al., 2002). GRA1 protein has been shown to be up-regulated in sporulated oocysts as well (Tilley et al., 1997; Possenti et al., 2013). The biological and clinical relevance of these differences remain to be investigated using functional assays.

Previous studies have shown that certain proteins might be functional in certain life-cycle stages. For example, while the homoserine kinase has been observed in the proteome of
FIGURE 4 | GO enrichment analysis of DEPs of O vs. T, T vs. C and C vs. O. DEPs in each group were sorted into three categories. The x-axis means different GO terms. The y-axis represents the number of proteins in the indicated categories. (A–C) represent GO enrichment analysis of DEPs for O vs. T, T vs. C and C vs. O, respectively. O, oocysts; T, tachyzoites; C, bradyzoites-containing cysts.

oocysts (Possenti et al., 2013), genes encoding for homoserine kinase (TGME49_216640) and other enzymes in the threonine biosynthesis pathway, such as aspartokinase (TGME49_227090), aspartate-semialdehyde dehydrogenase (TGME49_205420), and threonine synthase (TGME49_220840), are known to be expressed at low levels in the tachyzoite stage. In agreement
FIGURE 5 | KEGG pathway analysis of DEPs of O vs. T, T vs. C and C vs. O. The x-axis represents different KEGG pathways. The y-axis represents the number of proteins. (A–C) represent KEGG pathway analysis of DEPs of O vs. T, T vs. C and C vs. O, respectively. O, oocysts; T, tachyzoites; C, bradyzoites-containing cysts.
with these studies our results based on comparing oocysts to tachyzoites’ DEPs showed kinase activity amongst the top five enriched GO terms for differentially regulated proteins within molecular function. Our study also identified proteins with greater abundance that were involved in biological process, such as cellular nitrogen compound metabolic process, biosynthetic process, small molecule metabolic process, cellular protein modification process, and DNA metabolic process in the tachyzoites compared to oocysts. This finding supports the higher bioenergetics and metabolic need of *T. gondii* replicative forms (tachyzoites), which rely heavily on glucose uptake and glycolysis for generation of ATP and other intermediates required for energy generation and replication (Al-Anouti et al., 2004).

The ribosome is the factory for protein synthesis that sustains the development of biological organisms. It is assembled from

---

**TABLE 1 | Expression analysis of *Toxoplasma gondii* ribosomal proteins (TgRP).**

| TgRP | O vs. T | T vs. C | C vs. O |
|------|---------|---------|---------|
| S2   | —       | —       | —       |
| S3   | ↑       | ↓       | —       |
| S3A  | —       | ↓       | —       |
| S4   | ↑       | ↓       | —       |
| S5   | ↑       | ↓       | —       |
| S6   | ↑       | ↓       | —       |
| S7   | ↑       | ↓       | —       |
| S8   | ↑       | ↓       | —       |
| S9   | ↑       | ↓       | —       |
| S10  | ↑       | —       | —       |
| S11  | —       | ↓       | ↑       |
| S12  | —       | —       | —       |
| S13  | ↑       | —       | —       |
| S14  | ↑       | —       | —       |
| S15  | ↑       | —       | —       |
| S15A | ↑       | —       | —       |
| S16  | ↑       | —       | —       |
| S17  | ↑       | —       | —       |
| S18  | —       | —       | —       |
| S19  | —       | —       | —       |
| S20  | —       | —       | —       |
| S21  | —       | —       | —       |
| S22  | —       | —       | —       |
| S23  | ↑       | —       | —       |
| S24  | ↑       | —       | —       |
| S25  | ↑       | —       | —       |
| S26  | ↑       | —       | —       |
| S27  | —       | —       | —       |
| S27A | —       | —       | —       |
| S28  | —       | —       | —       |
| S29  | —       | —       | —       |
| S30  | —       | —       | —       |
| S31  | —       | —       | —       |
| S32  | —       | —       | —       |
| S33  | —       | —       | —       |
| S34  | —       | —       | —       |
| S35  | —       | —       | —       |
| S36  | —       | —       | —       |
| S37  | —       | —       | —       |
| S37A | —       | —       | —       |
| S38  | ↑       | —       | —       |
| L3   | ↑       | —       | —       |
| L4   | ↑       | —       | —       |
| L5   | ↑       | —       | —       |
| L6   | ↑       | —       | —       |
| L7   | ↑       | —       | —       |
| L7A  | ↑       | —       | —       |
| L8   | ↑       | —       | —       |
| L9   | ↑       | —       | —       |
| L10  | —       | —       | —       |

↑, upregulated; ↓, downregulated; —, non-significant changes.

O, oocysts; T, tachyzoites; C, bradyzoites-containing cysts.
both rRNA and ribosomal proteins (Meyuhas, 2000). The synthesis and expression of ribosomal proteins is higher in rapidly dividing cells and are regulated when the cell is under stress or is stimulated by growth factors (Pearson and Haber, 1980; Ju and Warner, 1994; Zhang et al., 2013). Various coccidian protozoan organisms are known to regulate the transcription of ribosome biosynthesis in order to adapt to changes that accompany stage transitions during their developmental life-cycles (Meyuhas, 2000; Cleary et al., 2002). *Toxoplasma gondii* contains 79 different ribosomal proteins, whose encoding genes are randomly distributed across the *T. gondii* genome (Tilley et al., 1997; Van Poppel et al., 2006). Seventy-one of the 79 ribosomal protein loci are distributed as single loci across the genome, but 8 loci are unique in that they are paired at four
locations in a head to head arrangement. In our study, oocysts and cysts showed the highest expression of ribosomal proteins compared to tachyzoites, indicating that these two stages have more metabolic flexibility, which may contribute to their ability to adapt to stress conditions. Oocysts are the environmental infective forms of *T. gondii*, and can survive for extensive periods of time outside the host (Torrey and Yolken, 2013). A previous study indicated that there are stage-associated differences in the expression of *T. gondii* ribosomal proteins (Schaap et al., 2005). Intriguingly, Hutson et al. showed via the generation of Δ*rps13* strain-deficient in ribosomal protein S13 (RPS13) that disruption of ribosomal proteins can lead to arrest of *T. gondii*
cell cycle, resulting in dormant parasites which can persist for several months in vitro, but without forming mature tissue cysts (Hutson et al., 2010). The same authors also demonstrated that immunization using the attenuated parasite Δrps13 strain can protect mice against subsequent challenge with wildtype T. gondii. However, it remains to be elucidated which of the differentially expressed ribosomal proteins identified in our study are essential for T. gondii ribosomes to function properly in the respective stages of the life-cycle.

CONCLUSION

In the present study, we used iTRAQ-based LC-MS/MS technique to compare the abundance of proteins in three life-cycle forms of T. gondii (oocyst, tachyzoite and bradyzoites-containing cyst). Our results revealed differences in the protein expression among the three life-cycle stages of this parasite, providing new insight into the adaptation mechanisms of these life-cycle forms to their habitats. These results lay the foundation for the understanding of the developmental biology of T. gondii, and should facilitate the discovery of novel therapeutic targets and the development of novel stage-specific diagnostic assays to augment available prevention measures to control toxoplasmosis.

AUTHOR CONTRIBUTIONS

XZ and DZ conceived and designed the experiments. ZW, CZ, and SH performed the experiments. DZ contributed reagents/materials/analysis tools. ZW analyzed the data and wrote the paper. ZW, HE and XZ critically revised the manuscript. All authors read and approved the final version of the manuscript.
FUNDING

Project financial support was kindly provided by the National Natural Science Foundation of China (Grant Nos. 31672549; 31230073; 31172316) and by the Fundamental Research Funds of Chinese Academy of Agricultural Sciences (Grant Nos. Y2016(C)05; 16YJ312016025; Y2017(C)06).

ACKNOWLEDGMENTS

We thank Guangzhou FitGene Biotechnology Co. Ltd. for technical assistance with the LC–MS/MS analysis.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: http://journal.frontiersin.org/article/10.3389/fmicb.2017.00985/full#supplementary-material

Availability of Data and Material

The datasets supporting the conclusions of this article are included within the article and its additional files. The mass spectrometry proteomics data of this article are available in the ProteomeXchange Consortium and the data set identifier is PXD003765.

Figure S1 | The chromatogram of SCX fractionation and LC–MS/MS analysis.

Table S1 | List of identified proteins between oocysts and tachyzoites after filtration (CV ≤ 0.5).

Table S2 | List of identified proteins between tachyzoites and cysts after filtration (CV ≤ 0.5).

Table S3 | List of identified proteins between cysts and oocysts after filtration (CV ≤ 0.5).

Table S4 | List of identified proteins between oocysts and tachyzoites using 99% confidence level (CV ≤ 0.5).

Table S5 | List of identified proteins between tachyzoites and cysts using 99% confidence level (CV ≤ 0.5).

Table S6 | List of identified proteins between cysts and oocysts using 99% confidence level (CV ≤ 0.5).

Table S7 | List of differentially expressed proteins (DEPs) between oocysts and tachyzoites (|log2 fold change| > 1 and P < 0.05).

Table S8 | List of differentially expressed proteins (DEPs) between tachyzoites and cysts (|log2 fold change| > 1 and P < 0.05).

Table S9 | List of differentially expressed proteins (DEPs) between cysts and oocysts (|log2 fold change| > 1 and P < 0.05).

REFERENCES

Al-Anouti, F., Tomavo, S., Parmley, S., and Ananvoranich, S. (2004). The expression of lactate dehydrogenase is important for the cell cycle of Toxoplasma gondii. J. Biol. Chem. 279, 52300–52311. doi: 10.1074/jbc.M409175200

Behnke, M. S., Zhang, T. P., Dubey, J. P., and Sibley, L. D. (2014). Toxoplasma gondii merozoite gene expression analysis with comparison to the life cycle discloses a unique expression state during enteric development. BMC Genomics 15:350. doi: 10.1186/1471-2164-15-350

Blader, I. J., Coleman, B. I., Chen, C. T., and Gubbels, M. J. (2015). Lytic cycle of Toxoplasma gondii: 15 years later. Annu. Rev. Microbiol. 69, 463–485. doi: 10.1146/annurev-micro-091014-104100

Böhme, W., Hoppert, M., and Gross, U. (1997). Stage differentiation of the protozoan parasite Toxoplasma gondii. Immunobiology 201, 248–254. doi: 10.1016/S0171-2985(99)80065-5

Cleary, M. D., Singh, U., Blader, I. J., Brewer, J. L., and Boothroyd, J. C. (2002). Toxoplasma gondii asexual development: identification of developmentally regulated genes and distinct patterns of gene expression. Eukaryotic Cell 1, 329–340. doi: 10.1128/EC.1.3.329-340.2002

Cohen, A. M., Rumpel, K., Coombs, G. H., and Wastling, J. M. (2002). Characterisation of global protein expression by two-dimensional electrophoresis and mass spectrometry: proteomics of Toxoplasma gondii. Int. J. Parasitol. 32, 39–51. doi: 10.1016/S0020-7519(01)00308-3

Craft, G. E., Chen, A., and Nairn, A. C. (2013). Recent advances in quantitative neuroproteomics. Methods 61, 186–218. doi: 10.1016/j.ymeth.2013.04.008

Dattoli, V. C., Veiga, R. V., Cunha, S. S., Pontes-de-Carvalho, L., Barreto, M. L., and Alcantara-Neves, N. M. (2011). Oocyst ingestion as an important transmission route of Toxoplasma gondii in Brazilian urban children. J. Parasitol. 97, 1080–1084. doi: 10.1645/GE-2836.1

Dubey, J. P. (2010). Toxoplasmosis of Animals and Humans, 2nd Edn. Boca Raton, FL: CRC Press.

Fritz, H. M., Bowyer, P. W., Bogyo, M., Conrad, P. A., and Boothroyd, J. C. (2012). Proteomic analysis of fractionated Toxoplasma oocysts reveals clues to their environmental resistance. PLoS ONE 7:e29955. doi: 10.1371/journal.pone.0029955

Hehl, A. B., Basso, W. U., Lippuner, C., Ramakrishnan, C., Okoniewski, M., and Walker, R. A. (2015). Asexual expansion of Toxoplasma gondii merozoites is distinct from tachyzoites and entails expression of non-overlapping gene families to attach, invade, and replicate within feline enterocytes. BMC Genomics 16:66. doi: 10.1186/s12864-015-1225-x

Herrmann, D. C., Bärwald, A., Maksimov, A., Pantchev, N., Vrhovec, M. G., Conraths, F. J., et al. (2012). Toxoplasma gondii sexual cross in a single naturally infected feline host: generation of highly mouse-virulent and avirulent clones, genotypically different from clonal types I, II and III. Vet. Res. 43:49. doi: 10.1186/1297-9716-43-39

Hutson, S. L., Mui, E., Kinsey, K., Witola, W. H., Behnke, M. S., El Bissati, K., et al. (2010). T. gondii RP promoters & knockdown reveal molecular pathways associated with proliferation and cell-cycle arrest. PLoS ONE 5:e1405. doi: 10.1371/journal.pone.0014057

Ju, Q., and Warner, J. R. (1994). Ribosome synthesis during the growth cycle of Saccharomyces cerevisiae. Yeast 10, 151–157. doi: 10.1002/yea.320100203

Klijstra, A., and Jongert, E. (2008). Control of the risk of human toxoplasmosis transmitted by meat. Int. J. Parasitol. 38, 1359–1370. doi: 10.1016/j.ijpara.2008.06.002

McLeod, R., Khan, A. R., Noble, G. A., Latkany, P., Jalbrzikowski, J., and Boyer, K. (2006). Severe sulfadiazine hypersensitivity in a child with reactivated congenital toxoplasmic chorioretinitis. Pediatr. Infect. Dis. J. 25, 270–272. doi: 10.1097/01.inf.0000202070.59190.9a

Meynha, O. (2000). Synthesis of the translational apparatus is regulated at the translational level. Eur. J. Biochem. 267, 6321–6330. doi: 10.1046/j.1432-1377.2000.01719.x

Montoya, J. G., and Liesenfeld, O. (2004). Toxoplasmosis. Lancet 363, 1965–1976. doi: 10.1016/S0140-6736(04)16412-2

Pearson, N. J., and Haber, J. E. (1980). Changes in regulation of ribosomal protein synthesis during vegetative growth and sporulation of Saccharomyces cerevisiae. J. Bacteriol. 143, 1411–1419.

Pierce, A., Unwin, R. D., Evans, C. A., Griffiths, S., Carney, L., Zhang, L., et al. (2008). Eight-channel iTRAQ enables comparison of the activity of six leukemogenic tyrosine kinases. Mol. Cell. Proteomics 7, 853–863. doi: 10.1074/mcp.M700251-MCP200

Possenti, A., Fratini, F., Fantozzi, L., Pozio, E., Dubey, J. P., Ponzi, M., et al. (2013). Global proteomic analysis of the oocyst/sporozoite of Toxoplasma
Toxoplasma gondii reveals commitment to a host-independent lifestyle. *BMC Genomics* 14:183. doi: 10.1186/1471-2164-14-183

Schaap, D., Arts, G., van Poppel, N. F., and Vermeulen, A. N. (2005). De novo ribosome biosynthesis is transcriptionally regulated in *Eimeria tenella*, dependent on its life cycle stage. *Mol. Biochem. Parasitol.* 139, 239–248. doi: 10.1016/j.molbiopara.2004.11.011

Staggs, S. E., See, M. J., Dubey, J. P., and Villegas, E. N. (2005). Obtaining highly purified *Toxoplasma gondii* oocysts by a discontinuous cesium chloride gradient. *J. Vis. Exp.* 3:33. doi: 10.3791/1420

Suzuki, Y., Wong, S. Y., Grumet, F. C., Fessel, J., Montoya, J. G., Zolopa, A. R., et al. (1996). Evidence for genetic regulation of susceptibility to toxoplasmic encephalitis in AIDS patients. *J. Infect. Dis.* 173, 265–268.

Tilley, M., Fichera, M. E., Jerome, M. E., Roos, D. S., and White, M. W. (1997). *Toxoplasma gondii* sporozoites form a transient parasitophorous vacuole that is impermeable and contains only a subset of dense-granule proteins. *Infect. Immun.* 65, 4598–4605.

Torrey, E. F., and Yolken, R. H. (2013). *Toxoplasma* oocysts as a public health problem. *Trends Parasitol.* 29, 380–384. doi: 10.1016/j.pt.2013.06.001

Van Poppel, N. F., Welagen, J., Vermeulen, A. N., and Schaap, D. (2006). The complete set of *Toxoplasma gondii* ribosomal protein genes contains two conserved promoter elements. *Parasitology* 133, 19–31. doi: 10.1017/S0031182006009954

White, M. W., Radke, J. R., and Radke, J. B. (2014). *Toxoplasma gondii* development - turn the switch on or off? *Cell. Microbiol.* 16, 466–472. doi: 10.1111/cmi.12267

Wu, W. W., Wang, G., Baek, S. J., and Shen, R. F. (2006). Comparative study of three proteomic quantitative methods, DIGE, cICAT, and iTRAQ, using 2D gel- or LC-MALDI TOF/TOF. *J. Proteome Res.* 5, 651–658. doi: 10.1021/pr0504050

Zhang, M., Joyce, B. R., Sullivan, W. J. Jr., and Nussenzweig, V. (2013). Translational control in *Plasmodium* and *Toxoplasma* parasites. *Eukaryotic Cell* 12, 161–167. doi: 10.1128/EC.00296-12

Zhou, C. X., Zhu, X. Q., Elsheikha, H. M., He, S., Li, Q., Zhou, D. H., et al. (2016). Global iTRAQ-based proteomic profiling of *Toxoplasma gondii* oocysts during sporulation. *J. Proteomics* 148, 12–19. doi: 10.1016/j.jprot.2016.07.010

Zhou, D. H., Yuan, Z. G., Zhao, F. R., Li, H. L., Zhou, Y., Lin, R. Q., et al. (2011). Modulation of mouse macrophage proteome induced by *Toxoplasma gondii* tachyzoites in vivo. *Parasitol. Res.* 109, 1637–1646. doi: 10.1007/s00436-011-2435-z

Zhou, D. H., Zhao, F. R., Nisbet, A. J., Xu, M. J., Song, H. Q., Lin, R. Q., et al. (2014). Comparative proteomic analysis of different *Toxoplasma gondii* genotypes by two-dimensional fluorescence difference gel electrophoresis combined with mass spectrometry. *Electrophoresis* 35, 533–545. doi: 10.1002/elps.201300044

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2017 Wang, Zhou, Elsheikha, He, Zhou and Zhu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.